logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 865 2352511, +7 865 2353229.

E-mail
medvestnik@stgmu.ru

Personalized management of patients with BRCA 1/2-associated breast cancer : from diagnosis to treatment

[Reviews]
Anastasia Mikhailovna Danishevich; Lyudmila Grigorievna Zhukova; Maria Vladimirovna Vorontsova; Tatiana Sergeevna Lisitsa; Maria Mikhailovna Litvinova; Natalya Bodunova;

Breast cancer is one of the most pressing problems in healthcare worldwide. It is widely known that the success of breast tumors treatment directly depends on the stage at which the neoplasm was diagnosed. Given the rapid growth rates and aggressive nature of inherited breast cancer forms, the introduction of precision medicine methods on the basis of cancer clinics, namely medical genetic counseling and DNA diagnostics, is becoming more and more popular. This review describes in detail the clinical features of hereditary BRCA-associated breast cancer, the main stages of medical and genetic counseling and the possibilities of molecular genetic diagnosis, as well as the most relevant international and Russian national clinical recommendations for diagnosis, treatment and prevention of malignant neoplasms in this group of patients.

Download

References:
1. Kaprin A. D., Starinsky V. V., Petrova G. V. Zlokachestvennye novoobrazovaniya v Rossii v 2017 godu (zabolevayemost i smertnost). M.: MNIOI im. P. A. Gertsena, 2018. (In Russ.).
2. Soukupová J., Lhotová K., Zemánková P., Vočka M., Janatová M. [et al.]. Contribution of massive parallel sequencing to diagnosis of hereditary ovarian cancer in the Czech Republic. Klin. Onkol. 2019;32(Suppl.2):2S72-2S78. https://doi.org/10.14735/amko2019S72
3. Takaoka M., Miki Y. BRCA1 gene: function and deficiency. Int. J. Clin. Oncol. 2018;23(1):36-44. https://doi.org/10.1007/s10147-017-1182-2
4. D’Andrea A. D., Grompe M. The fanconi anaemia/BRCA pathway. Nat. Rev. Cancer. 2003;3(1):23-34. https://doi.org/10.1038/nrc970
5. Engel C., Fischer C. Breast cancer risks and risk prediction models. Breast Care. 2015;10(1):7-12. https://doi.org/10.1159/000376600
6. Sopik V., Phelan C., Cybulski C., Narod S. A. BRCA1 and BRCA2 mutations and the risk for colorectal cancer. Clin. Genet. 2015;87(5):411-418. https://doi.org/10.1111/cge.12497
7. Dhawan M., Ryan C.J., Ashworth A. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities. Oncologist. 2016;21(8):940-945. https://doi.org/10.1634/theoncologist.2016-0135
8. Metcalfe K. A., Poll A., Royer R., Llacuachaqui M., Tulman A. [et al.]. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J. Clin. Oncol. 2010;28(3):387-391. https://doi.org/10.1200/JCO.2009.25.0712
9. Kurian A. W. BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications. Curr. Opin. Obstet. Gynecol. 2010;22(1):72-78. https://doi.org/10.1097/gco.0b013e328332dca3
10. Evans D. G., Shenton A., Woodward E., Lalloo F., Howell A., Maher E. R. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer. 2008;8:155. https://doi.org/10.1186/1471-2407-8-155
11. Lyubchenko L. N., Bateneva Ye. I. Mediko-geneticheskoye konsultirovaniye i DNK-diagnostika pri nasledstvennoy predraspolozhennosti k raku molochnoy zhelezy i raku yaichnikov. M.: IG RONTs, 2014. (In Russ.).
12. Mavaddat N., Barrowdale D., Andrulis I. L., Domchek S. M., Eccles D. [et al.]. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol. Biomarkers Prev. 2012;21(1):134-147. https://doi.org/10.1158/1055-9965.EPI-11-0775
13. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007;25(11):1329-1333. https://doi.org/10.1200/JCO.2006.09.1066
14. Lang G. T., Shi J. X., Hu X., Zhang C. H., Shan L. [et al.]. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. Int. J. Cancer. 2017;141(1):129-142. https://doi.org/10.1002/ijc.30692
15. Girolimetti G., Perrone A. M., Santini D., Barbieri E., Guerra F. [et al.]. BRCA-associated ovarian cancer: From molecular genetics to risk management. Biomed. Res. Int. 2014;2014:1-11. https://doi.org/10.1155/2014/787143
16. Yalaza M., Inan A., Bozer M. Male Breast Cancer. J. Breast. Heal. 2016;12(1):1-8. https://doi.org/10.5152/tjbh.2015.2711
17. Kast K., Rhiem K., Wappenschmidt B., Hauke J., Bluemcke B. [et al.]. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J. Med. Genet. 2016;53(7):465-471. https://doi.org/10.1136/jmedgenet-2015-103672
18. Daly M. B., Pilarski R., Berry P. M., Buys S. S., Dicson P. [et al.]. NCCN: Clincial Practice Guidelines in Oncology Genetic/ familial high – risk assessment: breast and ovarian. NCCN, 2019.
19. Snigireva G. P., Rumyantseva V. A., Novikova Ye. I., Novitskaya N. N., Telysheva Ye. N. [i dr.]. Algoritm molekulyarno-geneticheskogo obsledovaniya dlya vyyavleniya nasledstvennogo BRCA-assotsiirovannogo raka molochnoy zhelezy. Almanakh klinicheskoy meditsiny. – Almanac of Clinical Medicine. 2019;47(1):54-65. (In Russ.).
20. Revelli A., Salvagno F., Delle Piane L., Casano S., Evangelista F. [et al.]. Fertility preservation in BRCA mutation carriers. Minerva Ginecol. 2016;68(5):587-601. Available at: https://doi.org/pubmed.ncbi.nlm.nih.gov/26997146/. Accessed November 18, 2017.
21. Peccatori F. A., Mangili G., Bergamini A., Bergamini A., Filippi F. [et al.]. Fertility preservation in women harboring deleterious BRCA mutations: Ready for prime time? Hum. Reprod. 2018;33(2):181-187. https://doi.org/10.1093/humrep/dex356
22. Kasum M., Beketić-Orešković L., Orešković S. Subsequent pregnancy and prognosis in breast cancer survivors. Acta Clin. Croat. 2014;53(3):334-341. https://doi.org/pubmed.ncbi.nlm.nih.gov/25509244/
23. Weigel S., Heindel W., Heidrich J., Hense H. W., Heidinger O. Digital mammography screening: sensitivity of the programme dependent on breast density. Eur. Radiol. 2017;27(7):2744-2751. https://doi.org/10.1007/s00330-016-4636-4
24. Vreemann S., Gubern-Mérida A., Schlooz-Vries M. S., Bult P., Gils C. H. V. [et al.]. Influence of risk category and screening round on the performance of an MR imaging and mammography screening program in carriers of the BRCA mutation and other women at increased risk. Radiology. 2018;286(2):443-45 . https://doi.org/10.1148/radiol.2017170458
25. Portnoy S. M., Lyubchenko L. N. Rekomendatsii ROOM po diagnostike i lecheniyu nasledstvennogo RMZh. Obshcherossyskaya obshchestvennaya organizatsiya «Rossyskoye obshchestvo onkomammologov», 2014. (In Russ.).
26. Breast Cancer: Breast Cancer Information & Overview. American Cancer Society. https://www.cancer.org/cancer/breast-cancer.html. Accessed: 2017.
27. Budik Yu. A. Otsenka effektivnosti mastektomii u bolnykh geneticheski obuslovlennym rakom molochnoy zhelezy. FGBNU «RONTs imeni N. N. Blokhina» MZ RF, 2015. (In Russ.).
28. Paluch-Shimon S., Cardoso F., Sessa C., Balmana J., Cardoso M. J. [et al.]. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann. Oncol. 2016;27:v103-v110. https://doi.org/10.1093/annonc/mdw327
29. Zhukova L. G., Zikiryakhodzhayev A. D., Koroleva I. A., Nazarenko A. V., Parokonnaya A. A. [i dr.]. Rak molochnoy zhelezy. Ministerstvo zdravookhraneniya rossyskoy Federatsii. Klinicheskiye rekomendatsii, 2018. (In Russ.).
30. King M. C., Wieand S., Hale K., Lee M., Walsh T. [et al.]. Tamoxifen and breast cancer incidence among women with inherited mutations in brca1 and brca2 national surgical adjuvant breast and bowel project (nsabp-p1) breast cancer prevention trial. J. Am. Med. Assoc. 2001;286(18):2251-2256. https://doi.org/10.1001/jama.286.18.2251
31. Tschernichovsky R., Goodman A. Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act. Oncologist. 2017;22(4):450-459. https://doi.org/10.1634/theoncologist.2016-0444
32. Marchetti C., De Felice F., Boccia S., Sassu C., Di Donato V. [et al.]. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis. Crit. Rev. Oncol. Hematol. 2018;132:111-115. https://doi.org/10.1016/j.critrevonc.2018.09.018
33. Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer Clinical Guideline; National Institute for Heralth and Care Excellence Clinical guideline. 2013;1-253. Available at: https://www.nice.org.uk/guidance/cg164. Accessed November 18, 2017.
34. Synowiec A., Wcisło G., Bodnar L., Gajsowska-Bodnar A., Szczylik C. Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers. Ginekol. Pol. 2014;85(5):377-381. https://doi.org/10.17772/gp/1735
35. Bevers B. T., Ward H. J., Arun K. B., Golditz A. G., Daly B. M. [et al.]. NCCN: Clincial Practice Guidelines in Oncology: Breast Cancer. 2019; version 1. 36. Von Minckwitz G., Hahnen E., Fasching P.A., Mandeli J., Bleiweiss I., Tiersten A. Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (g BRCA) mutation and triple-negative breast cancer (TNBC): Results from GeparSixto. J. Clin. Oncol. 2014;32(Suppl.15):1005-1005. https://doi.org/10.1200/jco.2014.32.15_suppl.1005
37. AstraZeneca Pharmaceuticals LP. AstraZeneca Pharmaceuticals LP. LYNPARZA® (Olaparib) Tablets for Oral Use. Wilmington, DE; 2017. www.fda.gov/medwatch
38. Kim G., Ison G., McKee A. E., Zhang H., Tang S. [et al.]. FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin. Cancer Res. 2015;21(19):4257-4261. https://doi.org/10.1158/1078-0432.CCR-15-0887
39. AstraZeneca Pharmaceuticals LP. AstraZeneca Pharmaceuticals LP. LYNPARZA® (Olaparib) Tablets for Oral Use. Wilmington, DE; 2018. www.fda.gov/medwatch
40. Robson M., Ruddy K. J., Im S-A., Senkus E., Xu B. [et al.]. Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice (TPC). Ann. Oncol. 2017;28:v96. https://doi.org/10.1093/annonc/mdx365.053
41. Robson M., Im S.-A., Senkus E., Xu B., Domchek S. M. [et al.]. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N. Engl. J. Med. 2017;377(6):523-533. https://doi.org/10.1056/nejmoa1706450
42. Barber L. J., Sandhu S., Chen L., Campbell J., Kozarewa I. [et al.]. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 2013;229(3):422-429. https://doi.org/10.1002/path.4140
43. Domchek S. M., Postel-Vinay S., Im S. A., Park Y. H., Delord J.-P. [et al.]. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet. Oncol. 2020;21(9):1155-1164. https://doi.org/10.1016/S1470-2045(20)30324-7
44. Litton J., Rugo H., Ettl J., Hurvitz S., Gonçalves A. [et al.]. Abstract GS6-07: EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. In: Cancer Research. Vol 78. Aan Association for Cancer Research (AACR); 2018:GS6-07-GS6-07. https://doi.org/10.1158/1538-7445.sabcs17-gs6-07
45. Tesaro Inc. A. Phase III Trial of Niraparib Versus Physician’s Choice in HER2 Negative, Germline BRCA Mutation – positive Breast Cancer Patients (BRAVO) 2017. https://doi.org/clinicaltrials.gov/ct2/show/NCT01905592
46. Lecarpentier J., Silvestri V., Kuchenbaecker K., Barrowdale D., Dennis J. [et al.]. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J. Clin. Oncol. 2017;35(20):2.

Keywords: hereditary breast cancer, germinal mutations, BRCA1/2 genes, individualized treatment, cancer prevention, clinical recommendations, DNA diagnostics


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy